What Do the Terms in a Chinese CAR-T Treatment Record Mean?
A Chinese CAR-T treatment record contains the product name, the cell type, the collection and infusion dates, the monitoring period, any complications such as cytokine release syndrome (CRS) and neurotoxicity (ICANS), and the follow-up plan. Each of these sections has its own terminology. Misreading the product name, the CRS grade, or the follow-up plan can change what your home team understands about your treatment abroad.
Quick Answer
A Chinese CAR-T treatment record typically contains six key sections: product name (产品名称), cell type and target (细胞类型与靶点), collection and infusion dates (采集与回输日期), monitoring period (监测期), complications (并发症, especially CRS and ICANS), and follow-up plan (随访计划). The highest-risk terms are the product name (which may be a Chinese brand name, not an international generic name), the CRS grade (which uses a standardized 1–4 scale), and the follow-up plan (which your home oncologist will rely on after you return). A CAR-T record is a clinical document written for the treating team, not a patient-facing explanation.
"The CAR-T record is just a summary — the details don't matter once I go home." — Wrong. The CAR-T record is what your home oncologist will rely on if you develop delayed side effects, if you need follow-up monitoring, or if a complication occurs after you return. A misread product name, a misread CRS grade, or a missed follow-up instruction can change what your home team does next.
Who This Page Is NOT For
This page is not a tool to interpret your own CAR-T record, and it is not a substitute for the explanation given by the treating hospital. It is for patients and families who have received a Chinese CAR-T treatment record and want to understand its structure and terminology — so they can ask better questions of the treating team and of their home oncologist. Only the treating hospital and your treating oncologist can interpret the document for your specific case.
The Six Sections of a Chinese CAR-T Treatment Record
Most Chinese CAR-T treatment records follow a standard structure. Knowing the sections helps you find the information you need — and helps you notice what is missing.
1. 产品名称 — Product name
The name of the CAR-T product used. It may be a Chinese brand name, a Chinese generic name, or an international name.
- Chinese brand name (for example, a domestic product)
- Chinese generic name
- International nonproprietary name, if listed
2. 细胞类型与靶点 — Cell type and target
Which immune cells were engineered and which antigen they target.
- Cell type: autologous T cells (自体) or allogeneic (异体)
- Target: CD19, BCMA, CD22, or dual target
- Vector type, if listed
3. 采集与回输日期 — Collection and infusion dates
The date the patient's cells were collected (leukapheresis) and the date the engineered cells were infused.
- 采集 (cǎi jí) = collection
- 回输 (huí shū) = infusion
- Bridge therapy between collection and infusion, if any
4. 监测期 — Monitoring period
The period after infusion during which the patient is monitored closely for side effects.
- Typically 2–4 weeks in or near the treating center
- Daily or frequent blood tests
- Monitoring for CRS and ICANS
5. 并发症 — Complications
Any complications that occurred during the monitoring period, especially cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
- 细胞因子释放综合征 (CRS)
- 免疫效应细胞相关神经毒性综合征 (ICANS)
- Grade (1–4) and management
6. 随访计划 — Follow-up plan
The plan for follow-up after discharge, including when to return, what tests to do, and what symptoms to watch for.
- Follow-up interval
- Recommended tests (blood counts, imaging)
- Warning signs to report
Terms Most Often Misread
| Chinese term | Pinyin | Approximate English | Why it is easy to misread |
|---|---|---|---|
| 自体 / 异体 | zì tǐ / yì tǐ | Autologous / allogeneic | Autologous means the cells came from the patient; allogeneic means they came from a donor. The two have different risk profiles and different follow-up requirements. |
| 靶点 | bǎ diǎn | Target (antigen) | The target (for example, CD19 or BCMA) determines which cancers the product is designed for. A product targeting one antigen is not interchangeable with a product targeting another. |
| 采集 | cǎi jí | Collection (leukapheresis) | The date the patient's cells were collected, not the date of infusion. The two dates are often weeks apart. |
| 回输 | huí shū | Infusion | The date the engineered cells were infused. This is the date from which the monitoring period is counted. |
| 细胞因子释放综合征 | xì bāo yīn zǐ shì fàng zōng hé zhēng | Cytokine release syndrome (CRS) | A common and potentially serious complication. The grade (1–4) matters — a grade 1 CRS is very different from a grade 4 CRS. |
| 免疫效应细胞相关神经毒性综合征 | miǎn yì xiào yìng xì bāo xiāng guān shén jīng dú xìng zōng hé zhēng | ICANS | Neurotoxicity after CAR-T. Like CRS, the grade matters, and the symptoms can be subtle at first (confusion, tremor, speech difficulty). |
| 随访 | suí fǎng | Follow-up | Often paired with an interval (for example, "1个月后随访" = follow-up in 1 month). Missing the interval can delay necessary review. |
| 复发 / 进展 | fù fā / jìn zhǎn | Relapse / progression | Relapse means the disease returned after a period of response; progression means it grew during or after treatment. The two may imply different next steps. |
A Fictional Example: Reading a CAR-T Treatment Record
The example below is fictional. It is used only to show the structure and terminology of a CAR-T treatment record. It is not derived from any real patient's records.
How to read this example: The product name identifies the CAR-T product and its target (CD19). The cell type section confirms that the cells were autologous (from the patient). The collection and infusion dates are weeks apart — this is normal, because the cells need time to be engineered and expanded in the lab. The complications section describes a grade 2 CRS that resolved with tocilizumab, and notes that no ICANS occurred. The follow-up plan gives specific intervals, tests, and warning signs. All six sections matter; none should be skipped.
Questions to Bring to the Treating Team and Your Home Oncologist
These questions are educational. They are not an assessment of your case. Review the answers with the treating hospital and your licensed oncologist.
What is the exact product name, and what is its international equivalent?
Ask for the generic name and the target antigen, so your home team can look up the product in international sources.
Were the cells autologous or allogeneic?
The two have different risk profiles and different follow-up requirements.
Did I have CRS or ICANS, and if so, what grade?
Ask for the grade and the management, so your home team knows what to watch for.
What is the exact follow-up plan — which tests, at what intervals, and where?
Ask for the schedule in writing, including the specific tests and the interval.
What symptoms should prompt me to return earlier than scheduled?
Ask for a specific list — fever, confusion, tremor, speech difficulty, and any other warning signs relevant to CAR-T.
Is there a translated or English version of the CAR-T record available?
If not, ask whether the hospital can provide a structured summary in English for your home oncologist.
Continue Your Research
Related reference pages on Chinese medical documents and cancer treatment.
What Do 符合, 考虑为, 倾向, and 不除外 Mean?
How four modifier terms express different levels of diagnostic certainty in a Chinese pathology report.
How Do I Match a Chinese Drug Name to Its Generic Name?
Identify a Chinese cancer drug by brand, active ingredient, or generic name.
What Do the Terms in a Chinese Discharge Summary Mean?
The document you hand to your home oncologist — diagnosis, procedures, medications, discharge status, and follow-up.
Frequently Asked Questions
What is the difference between autologous and allogeneic CAR-T?
Autologous CAR-T uses the patient's own T cells, collected and engineered for that patient. Allogeneic CAR-T uses T cells from a healthy donor, engineered to be given to multiple patients. The two have different risk profiles (for example, graft-versus-host disease is a concern with allogeneic products) and different follow-up requirements. The record should state clearly which one was used.
Does a grade 4 CRS mean the treatment failed?
No. The grade of CRS describes the severity of the complication, not the effectiveness of the treatment. A grade 4 CRS is a severe event that requires intensive management, but it does not by itself indicate that the CAR-T therapy failed. Only the treating team can interpret the grade in the context of your clinical course and response.
Why are the collection and infusion dates so far apart?
Because the cells need time to be engineered and expanded in the laboratory. After collection (leukapheresis), the T cells are genetically modified, expanded to a therapeutic dose, and quality-tested before infusion. This process typically takes several weeks, and the exact time depends on the product and the center. The two dates are often weeks apart, and this is normal.
What is ICANS, and why does it matter after I go home?
ICANS (immune effector cell-associated neurotoxicity syndrome) is a neurological complication that can occur after CAR-T. Symptoms can include confusion, tremor, speech difficulty, and, in severe cases, seizures. Most cases occur during the monitoring period, but delayed cases have been reported. This is why the follow-up plan includes specific warning signs — if you or your family notice any of them after you return home, contact your home oncologist promptly.
What does "复发" or "进展" mean in the follow-up section?
"复发" (relapse) means the disease returned after a period of response. "进展" (progression) means the disease grew during or after treatment. The two terms may imply different next steps, and the distinction matters for the conversation with your treating team. If either term appears in your record, ask the treating team to clarify what it refers to in your specific case.
Where can I find the full list of Chinese medical document reference pages?
This page is part of a series of question-based reference pages on Chinese medical documents. Related pages cover pathology certainty terms, drug-name matching, high-risk mistranslation terms, discharge summaries, laboratory reports, and imaging reports. You can find the full list on the Evidence Hub.
Sources & References
- 国家卫生健康委员会. 医疗机构临床实验室管理办法. (National Health Commission of the People's Republic of China. Management Measures for Clinical Laboratories in Medical Institutions.) nhc.gov.cn ↗
- 中华医学会血液学分会. CAR-T细胞治疗相关毒性管理专家共识. (Chinese Medical Association Hematology Branch. Expert Consensus on Management of CAR-T Cell Therapy-Related Toxicities.)
- 中国抗癌协会血液肿瘤专业委员会. CAR-T细胞治疗临床应用指南. (Chinese Anti-Cancer Association Hematology Oncology Committee. Clinical Application Guidelines for CAR-T Cell Therapy.)
- Neelapu SS, et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities. Nature Reviews Clinical Oncology. 2018. PubMed ↗
- Lee DW, et al. ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells. Biology of Blood and Marrow Transplantation. 2019. PubMed ↗